Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
PureTech Share News (PRTC)
PRTC Share
Price
PRTC Share
News
PRTC Share
Chat
PRTC Share
Trades101
PRTC
Live RNS
PRTC Share
Charts
PRTC Level 2
Console
PRTC Live
Share Price
PRTC Broker
Ratings
PRTC Directors
Deals
PRTC Financial
Diary
PRTC
Fundamentals
PRTC Short
Positions2
PRTC
Media
PRTC Company
Research
PRTC Company
Timeline2
Share Price Information for PureTech (PRTC)
Last checked at -
Last checked at 
Intraday PureTech Share Chart
Friday broker round-up
PageGroup: Credit Suisse reiterates outperform with a target price of 500p.
ASOS: RBC Capital Markets reiterates outperform with a target price of 4,100p.
Pearson: Deutsche Bank reiterates hold with a target price of 500p.
AVEVA: Goldman Sachs reiterates neutral with a target price of 5,200p.
Unilever: Jefferies upgrades to buy with a target price of 5,000p.
PureTech: Liberum reiterates buy with a target price of 450p.
Rathbone Brothers: RBC Capital Markets upgrades to outperform with a target price of 2,240p.
Forterra: Berenberg reiterates hold with a target price of 340p.
Volution: Berenberg upgrades to buy with a target price of 280p.
BAE Systems: Morgan Stanley downgrades to equal weight with a target price of 660p.
Schroders: Citigroup downgrades to sell.
Ashmore Group: Citigroup initiates at neutral with a target price of 560p.
Latest PRTC News
- PureTech-founded Seaport reports positive GlyphAgo phase 1 data
9 Jun 2026 - PureTech Health notes pricing of Seaport Therapeutics for Nasdaq IPO
1 May 2026 - EARNINGS AND TRADING: Naked Wines eyes top-end earnings but sales flag
29 Apr 2026 - LONDON BRIEFING: AstraZeneca, Lloyds, GSK post first-quarter growth
29 Apr 2026 - UK earnings, trading statements calendar - next 7 days
22 Apr 2026 - PureTech Health's Seaport files for possible Nasdaq listing
13 Apr 2026 - EARNINGS AND TRADING: McBride proposes cash acquisition of Eurotab
2 Apr 2026 - PureTech says its pulmonary fibrosis drug granted orphan designation
20 Feb 2026
Related News
DIRECTOR DEALINGS: Lloyds Banking COO sells GBP1.0 million in shares
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and Friday and not...
IN BRIEF: BAE Systems starts third tranche of GBP1.5 billion buyback
BAE Systems PLC- London-based defence contractor - Commences the third tranche, worth up to GBP500 million, of its up to GBPBP1.5 billion, three-year ...
LONDON BRIEFING: Babcock raises annual dividend as revenue grows
(Alliance News) - Stocks were called higher on Monday after the US and Iran, mediators said, agreed to set up communications lines to keep the vital S...
PureTech News
PureTech-founded Seaport reports positive GlyphAgo phase 1 data
(Alliance News) - PureTech Health PLC on Tuesday highlighted positive phase 1 data from Seaport Therapeutics Inc for GlyphAgo, supporting plans to adv...
PureTech Health notes pricing of Seaport Therapeutics for Nasdaq IPO
(Alliance News) - PureTech Health PLC on Friday noted the pricing of its founded entity Seaport Therapeutics Inc for its planned initial public offeri...
EARNINGS AND TRADING: Naked Wines eyes top-end earnings but sales flag
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...
LONDON BRIEFING: AstraZeneca, Lloyds, GSK post first-quarter growth
(Alliance News) - AstraZeneca, Lloyds Banking Group and GSK report higher earnings in the first quarter.
PureTech Health's Seaport files for possible Nasdaq listing
(Alliance News) - PureTech Health PLC on Monday said that Seaport Therapeutics Inc, founded by PureTech, had filed for an initial public offering on N...
EARNINGS AND TRADING: McBride proposes cash acquisition of Eurotab
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...
PureTech says its pulmonary fibrosis drug granted orphan designation
(Alliance News) - PureTech Health PLC said on Friday its drug treating idiopathic pulmonary fibrosis, deupirfenidone, has been designated as an orphan...
Follow the stocks
